ClinicalTrials.gg
RecruitingNCT06236269ACROSS-TROP2Updated Jul 19, 2024

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

A Phase 2 interventional study of Sacituzumab Govitecan in Breast Cancer Stage IV, sponsored by SOLTI Breast Cancer Research Group. Recruiting at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by SOLTI Breast Cancer Research Group · Phase 2, Interventional, and Diagnostic

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing sacituzumab govitecan in Breast Neoplasms — 17 open to participants now, 25 under way, 4 of them phase 3. sacituzumab govitecan · Breast Neoplasms.

Planned enrollment
17th of 28
50 · median 75
Started
2024
with 4 others
Phase 2
16 of 28
13 open now
Primary completion
2026-02
later than 1 of 24 live
Registered
16th of 28
by date

Among the 28 studies testing sacituzumab govitecan in Breast Neoplasms, this one is the 17th largest by planned enrollment, is one of 5 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 1 of the 24 other live ones, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 28 studies testing sacituzumab govitecan in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing sacituzumab govitecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, single arm, non-randomized, multicenter phase II study for the identification of predictive biomarkers of sacituzumab govitecan benefit and the understanding of key resistance mechanisms in HR+/HER2- advanced/metastatic breast cancer patients

Read the detailed description

This study will include patients with HR+/HER2- advanced/metastatic breast cancer who have progressed on prior endocrine therapy and CDK4/6i and who have received up to 1 prior regimen of chemotherapy or ADC for metastatic breast canncer.

The primary objective is to evaluate the change in the CelTIL score, a combined biomarker based on stromal tumor-infiltrating lymphocytes and tumor cellularity, as surrogate of treatment response after one dose of sacituzumab govitecan (SG).

Patients who fulfil all eligibility criteria will start SG at 10 mg/kg as an IV infusion on Days 1 and 8 of a 21-day cycle. SG will be administered continuously until progression of the disease, unacceptable toxicity, investigator's decision, withdrawal of consent, or other reasons described in the protocol.

Tumor tissue (newly obtained) will be sent to a central laboratory. After 2 weeks(14-21 days) of treatment a new biopsy of the same lesion will be performed. Tumor biopsy will be also performed at disease progression / EoT. In addition, blood samples (for ctDNA) will be collected at C1D1, C2D1 and at progression / EoT for exploratory objectives.

Imaging will be performed prior to day 1 of treatment and target and non-target lesions will be identified as per RECIST 1.1. Tumor assessments will be performed every 9 weeks until the start of a new anti-cancer therapy, withdrawal of consent, progression of disease, death, or the end of the study, whichever occurs first. Tumor assessments will be performed on the specified schedule regardless of treatment delays. Tumor response will be assessed as per RECIST v.1.1.

Safety assessments will include the incidence, nature, and severity of AEs and laboratory abnormalities graded per the NCI CTCAE v.5.0. Laboratory safety assessments will include the regular monitoring of hematology, blood chemistry and pregnancy test.

03

Conditions studied

  • Breast Cancer Stage IV

Browse trials for

Keywords

  • sacituzumab govitecan
  • breast cancer
  • CelTIL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written form prior to any mandatory study specific procedures, sampling, and analyses.
  2. Patients must be male or female (pre/peri or ) ≥ 18 years of age.
  3. performance status of 0 or 1(see Appendix 1).
  4. or cytologically confirmed breast cancer with evidence of locally advanced disease, not amenable to resection or radiation therapy with curative intent or disease.
  5. HR+/- BC by local testing, not amenable to surgical therapy will be enrolled in this study.

    1. HER2 negativity is defined as either of the following by local laboratory assessment: IHC 0, IHC 1+ or IHC2+/in situ hybridization (ISH) negative as per the most recent American Society of Clinical Oncology (ASCO)-College of American Pathologists Guideline (CAP) guideline. If a patient has had multiple HER2 results after metastatic disease, the most recent test result prior screening period will be used to confirm eligibility.
    2. ER and/or PR positivity are defined as >1% of cells expressing HR via IHC analysis as per most recent ASCO-CAP guideline. If a patient has had multiple ER/PgR results after metastatic disease, the most recent test result prior screening period will be used to confirm eligibility.
  6. Disease to CDK4/6 inhibitors, defined as recurrence during or within 12 months after the end of treatment or progression during or within 6 months after the end of treatment for advanced/metastatic disease.
  7. No more than 1 prior systemic chemotherapy or antibody-drug conjugate (ADC) regimens for metastatic disease. Adjuvant or neoadjuvant therapy for early-stage disease will qualify as one of the required prior chemotherapy regimens if the development of unresectable, locally advanced, or metastatic disease occurred within a 12-month period of time of the therapy. Note: treatments for bone metastases (eg, bisphosphonates, denosumab, etc.), targeted therapies (eg, PARP inhibitors, CDK 4/6 inhibitors, immunotherapy etc.) and hormonal therapy are not considered as prior systemic chemotherapy treatments for advanced disease.
  8. Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting study treatment
  9. Measurable or non- but evaluable (identification of target and/or non-target lesions by Vs1.1).
  10. Patients must have a site of disease amenable to safely perform a , as per Investigator's assessment, and be a candidate for tumor biopsy according to the treating institution's guidelines.
  11. Possibility of performing a biopsy prior to the start of treatment and its repetition after 2 weeks (14-21 days) and at End of Treatment (EOT) on the same location. It will be provided formalin-fixed paraffin-embedded (FFPE) tumor block. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for quality prior to enrollment. Patients whose tumor tissue is not evaluable for central testing are not eligible. It is recommended to send the biopsy directly to the central lab after confirming the existence of a tumor, so as not to delay the inclusion, without the need to carry out IHC studies in the same sample.

    • Acceptable samples include core needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, bone or mucosal lesions or biopsies from bone metastases. Lymph node biopsies are also permitted.
    • Fine needle aspiration, brushing, cell pellet from pleural effusion and lavage samples are not acceptable.
  12. Patients must have normal organ and bone marrow function measured within 35 days prior to administration of study treatment as defined below:

    • ≥ 9.0 g/dL *
    • (ANC) ≥ 1.5 x 109/L*
    • count ≥ 100 x 109/L*
    • Total (TBL) ≤ 1.5 × (ULN) or ≤ 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia).
    • (SGOT) / ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present in which case, they must be ≤ 5x ULN
    • Creatinine ≤ 1.5 x ULN or estimated of ≥30mL/min using the Cockcroft-Gault equation.
    • Serum albumin >3 g/dL
    • (INR) or prothrombin time (PT) and either partial thromboplastin or activated partial thromboplastin time (aPTT) ≤ 1.5 ×ULN *Without transfusional or growth factor support within 1 week of study treatment initiation.
  13. Patients must have a ≥ 16 weeks.
  14. Male patients and female patients of who engage in heterosexual intercourse must agree to use protocol-specified method(s) of as described in Appendix 2.
  15. Willing and able to comply with the requirements and restrictions in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with -positive or TNBC disease.
  2. Other unless curatively treated with no evidence of disease for ≥3 years except: non-melanoma skin cancer, in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma or other malignant tumors with an expected curative outcome after medical monitor approval.
  3. Has unresolved toxicities from previous anticancer therapy (≥ version 5.0 grade 1) caused by previous cancer therapy, excluding alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to ≥Grade 2 for at least 2 months prior to enrollment and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, such as: Chemotherapy-induced neuropathy, Fatigue, Residual toxicities from prior IO treatment Grade 1 or Grade 2 endocrinopathies. Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  4. Patients may not be participating in a study with an agent or investigational device within 2 weeks or 5 half-lives, whichever is longer, prior to allocation. Patients participating in observational studies are eligible.
  5. Patients with symptomatic uncontrolled . Participants with a history of treated Central Nervous System (CNS) are eligible, provided they meet all of the following criteria:

    • Biopsiable disease outside the CNS is present.
    • No evidence of interim CNS progression between the completion of CNS directed therapy and the screening radiographic study.
    • Metastases are limited solely to cerebellar and supratentorial lesions.
    • Stable requirement for (≤ 20 mg oral prednisone or equivalent) or anticonvulsants during >4 weeks as therapy for CNS disease.
    • No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to enrolment.
    • No evidence of progression or haemorrhage after completion of CNS directed therapy.
    • Patients with spinal cord compression are excluded unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
  6. History of significant cardiovascular disease, defined as:

    • Class III or greater congestive heart failure or known of \< 40%.
    • Unstable angina or myocardial infarction within 6 months before enrolment.
    • History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of prolongation.
  7. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment.
  8. Have active serious infection requiring requiring IV antibiotics, antivirals, or antifungals.
  9. Have a known history of (HIV).
  10. Have active (defined as having a positive HbsAg test) or .

    1. For patients with a history of HBV infection, a hepatitis B core antibody test should be conducted at screening. If positive, hepatitis B DNA testing will be performed and if active HBV infection is ruled out, the patient may be eligible.
    2. Patients who are HCV antibody positive with polymerase chain reaction negative for HCV RNA may be eligible.
  11. Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  12. Has received a within 30 days prior to randomization.
  13. Prior treatment with Sacituzumab-govitecan.
  14. Known or severe (≥ Grade 3) or allergy to sacituzumab govitecan, their metabolites, or formulation .
  15. Requirement for ongoing therapy with or prior use of any prohibited medications listed in Section 7.5.
  16. Positive serum pregnancy test or women who are lactating (see Appendix 2).
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sacituzumab Govitecan

    Sacituzumab govitecan will be given on Days 1, 8 of a 21-day cycle at a dose of 10 mg/kg intravenously, continuously until progression of the disease or unacceptable toxicity.

    Drug: Sacituzumab Govitecan

Interventions

  • Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle

    Also known as: Trodelvy

06

What researchers measure

Primary outcomes

  1. CelTIL score

    Mean change in CelTIL score per central assessment between paired tumor samples in the overall population. CelTIL score = -0.8 x tumor cellularity (%) + 1.3 x tumor-infiltrating lymphocytes (TILs) (%). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect a range from 0 to 100 points.

    Time frame: baseline and at Cycle 2 Day 1 (14-21 days after treatment initiation)

Secondary outcomes

  1. Overall Response rate (ORR)

    proportion of patients with measurable disease with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  2. Clinical Benefit Rate (CBR)

    Proportion of patients with a best overall response of CR, PR or an overall lesion response of Stable Disease (SD) or Non- PR/Non-progression disease (PD) lasting ≥24 weeks, based on local investigator´s assessment according to RECIST v1.1.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  3. Progression free survival (PFS)

    Time from enrollment to the first occurrence of disease progression, as determined locally by the investigator through the use of RECIST v.1.1, or death from any cause, whichever occurs first.

    Time frame: From date of enrollment to disease progression or death from any cause,whichever came first, assessed up to approximately 9 months

  4. Duration of response (DoR)

    Time from the first occurrence of a documented objective response to disease progression, as determined locally by the investigator through use of RECIST v.1.1, or death from any cause, whichever occurs first.

    Time frame: From date of enrollment to disease progression or death from any cause,whichever came first, assessed up to approximately 9 months

  5. Time to response (TtR)

    Time from enrollment to the first objective tumor response (tumor shrinkage of ≥30%) observed for patients who achieved a CR or PR.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  6. Correlation between baseline TROP2 expression and the variation of CelTIL score

    Correlation between TROP2 mRNA baseline levels and changes in CelTIL score at C2D1.

    Time frame: Baseline and at the start of Cycle 2 (Day 1, cycle of 21 days)

  7. Correlation between TROP2 mRNA expression with TROP2 IHC expression

    Correlation coefficients between TROP2 mRNA and TROP2 IHC biomarkers.

    Time frame: Baseline

  8. Correlation between baseline TROP2 IHC expression with changes in CelTIL score

    Correlation between TROP2 IHC baseline levels and changes in CelTIL score at C2D1

    Time frame: Baseline and at the start of Cycle 2 (Day 1, cycle of 21 days)

  9. Clinical benefit according to TROP2 mRNA expression & TROP2 IHC expression at baseline.

    Association of TROP2 mRNA expression \& TROP2 IHC expression at baseline with ORR.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  10. Clinical benefit according to TROP2 mRNA expression & TROP2 IHC expression at baseline.

    Association of TROP2 mRNA expression \& TROP2 IHC expression at baseline with CBR.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  11. Clinical benefit according to TROP2 mRNA expression & TROP2 IHC expression at baseline.

    Association of TROP2 mRNA expression \& TROP2 IHC expression at baseline with PFS.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  12. Clinical benefit according to TROP2 mRNA expression & TROP2 IHC expression at baseline.

    Association of TROP2 mRNA expression \& TROP2 IHC expression at baseline with DoR.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  13. Clinical benefit according to TROP2 mRNA expression & TROP2 IHC expression at baseline.

    Association of TROP2 mRNA expression \& TROP2 IHC expression at baseline with TtR.

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  14. Correlation of CelTIL score at C2D1 with long-term outcome

    Correlation of CelTIL score at C2D1 with ORR, CBR, PFS, DoR, TtR

    Time frame: Until objective tumor response, assessed up to approximately 9 months

  15. Assess safety and tolerability of Sacituzumab Govitecan

    Incidence, seriousness, treatment-related and severity (grade) of Treatment Emergent Adverse Events (TEAEs) assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 5, including dose reductions, delays and treatment discontinuations.

    Time frame: Through study completion, from date of enrollment to end of study, assessed up to approximately 29 months after the first patient enrolled

07

Study locations

2 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2026, 23 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 23 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Feb 1, 2024
StartActual
Mar 15, 2024
Primary completionEst.
Feb 20, 2026
CompletionEst.
Feb 20, 2027
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06236269
Lead sponsor
SOLTI Breast Cancer Research Group
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Mar 15, 2024
Primary completion
Feb 20, 2026 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Jul 19, 2024

Study contacts

Mariana Paes Dias, PhD
Contact
mariana.paes@gruposolti.org
0034 609 384 751
Fernando Salvador, PhD
Contact
fernando.salvador@gruposolti.org
0034 616 194 478
Eva Ciruelos, MD
principal investigator · Hospital 12 de Octubre, Madrid/SOLTI
Mafalda Oliveira, MD
principal investigator · Hospital Vall d'Hebrón/SOLTI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion